Table 2.
Characteristic | RR | 95% CI | P |
---|---|---|---|
Age category, years | |||
12–20 | 1.00 | Reference | |
5–11 | 1.82 | 1.51–2.19 | < 0.0001 |
Sex | |||
Male | 1.00 | Reference | |
Female | 1.32 | 0.77–2.24 | 0.30 |
Village of residence | |||
Vingujini | 1.00 | Reference | |
Bomani | 1.64 | 1.02–2.64 | 0.04 |
Mwaembe | 1.31 | 0.69–2.47 | 0.40 |
Sawa Sawa | 1.43 | 0.81–2.52 | 0.21 |
Maigiza | 2.92 | 1.18–7.20 | 0.02 |
Vindungeni | 3.45 | 1.72–6.92 | 0.0005 |
Kisimachande | 1.81 | 1.07–3.07 | 0.03 |
Nganja | 3.78 | 2.24–6.36 | < 0.0001 |
Milalani | 3.23 | 1.97–5.29 | < 0.0001 |
Treatment in first year | |||
Praziquantel | 1.00 | Reference | |
None | NA | NA | NA |
Three doses of metrifonate | 1.16 | 0.97–1.39 | 0.09 |
One or two doses of metrifonate | 1.48 | 1.08–2.01 | 0.01 |
Missed, placebo, unknown | 2.14 | 1.35–3.40 | 0.001 |
Hematuria at entry | |||
None | 1.00 | Reference | |
Trace | 1.21 | 0.75–1.94 | 0.43 |
1+ | 1.30 | 1.00–1.71 | 0.05 |
2+ | 1.39 | 1.05–1.84 | 0.02 |
3+ | 1.63 | 1.26–2.11 | 0.0002 |
Sex/village interaction | |||
Male × Vingujini | 1.00 | Reference | |
Female × Bomani | 0.42 | 0.22–0.82 | 0.01 |
Female × Mwaembe | 1.30 | 0.58–2.88 | 0.52 |
Female × Sawa Sawa | 1.03 | 0.49–2.17 | 0.93 |
Female × Marigiza | 0.79 | 0.24–2.61 | 0.71 |
Female × Vindungeni | 0.53 | 0.17–1.62 | 0.27 |
Female × Kisimachande | 1.42 | 0.72–2.79 | 0.30 |
Female × Nganja | 0.49 | 0.23–1.05 | 0.07 |
Female × Milalani | 1.08 | 0.56–2.08 | 0.80 |
RR = relative risk; CI = confidence interval; NA = not applicable.